Clinical targets demonstrating promising activity in SCLC
Jean-Charles Soria, Amgen’s Senior vice president of Oncology within Global Development, shared a post by Jon Zugazagoitia on LinkedIn:
“The tumor microenvironment of SCLC is often “immune cold” (due to low T cell infiltration & high immune suppression), & frequently shows high levels of DNA damage response.
Despite these complexities, new clinical targets are now demonstrating promising activity: DLL3, B7H3, FucGM1& others.”
Facts and Hopes on Cancer Immunotherapy for Small Cell Lung Cancer
Authors: Jon Zugazagoitia, et al.
Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023